Cepheid (CPHD) - Medical Equipment - Deals and Alliances Profile

Date: October 18, 2016
Pages: 72
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C6BB6EA5AA0EN
Leaflet:

Download PDF Leaflet

Cepheid (CPHD) - Medical Equipment - Deals and Alliances Profile
Summary

Cepheid is a molecular diagnostic company which develops, manufactures, and markets accurate and easy-to-use molecular systems and tests for clinical and non-clinical markets. The company offers invitro diagnostic tests for health care associated infections, critical infectious diseases, sexual health, and oncology and genetics; systems that integrate sample preparation, DNA amplification and detection and analyze complex biological samples in our proprietary test cartridges; industrial reagents and parts and accessories for its systems. The company operates through its subsidiaries in France, Sweden, the US, Japan, Germany, South Africa, the UK, Belgium, Australia, the UAE, China, Italy, Singapore, Brazil, India, and Hong Kong. Cepheid is headquartered in Sunnyvale, California, the US.

Cepheid (CPHD) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.
Cepheid, Medical Equipment, Deals By Year, 2010 to YTD 2016
Cepheid, Medical Equipment Deals By Type, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals By Region, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals By Market, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals Summary, 2010 to YTD 2016
Cepheid, Medical Equipment, Deal Details
Partnerships
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics
Quidel Enters Into Licensing Agreement With Northwestern University And Northwestern Global Health Foundation
Novacyt Enters into Partnership with Cepheid
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University
InGen BioSciences Enters Into Distribution Agreement With Quidel
InGen BioSciences Enters Into Distribution Agreement With Diagnostic Hybrids
Life Technologies Enters Into Co-Marketing Agreement With Quidel
Cepheid Enters Into Co-Development Agreement With FIND
Cepheid Enters Into Collaboration With Novartis
Cepheid Terminates Licensing Agreement With Roche
Equity Offering
Quidel Completes Underwritten Public Offering Of US$60 Million
Debt Offering
Quidel Prices Public Offering of 3.25% Senior Notes Due 2020
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million
Acquisition
Danaher to Acquire Cepheid
Quidel Acquires AnDiaTec, Molecular Diagnostics Company
Quidel Acquires BioHelix, Molecular Diagnostic Company, For US$10 Million
Quidel Completes Acquisition Of Diagnostic HYBRIDS
Cepheid - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Financial Announcements
Jul 28, 2016: Cepheid Reports Second Quarter 2016 Results
Apr 28, 2016: Cepheid Reports First Quarter 2016 Results
Feb 02, 2016: Cepheid Reports Fourth Quarter And Full Year 2015 Results
Oct 20, 2015: Cepheid Reports 2015 Third Quarter Results
Oct 13, 2015: Cepheid Reports Preliminary Results For 2015 Third Quarter
Jul 23, 2015: Cepheid Reports 2015 Second Quarter Results
Apr 23, 2015: Cepheid Reports 2015 First Quarter Results
Jan 29, 2015: Cepheid Reports Fourth Quarter And Full Year 2014 Results
Corporate Communications
Feb 10, 2016: Cepheid Announces Appointment of President and Chief Operating Officer and Welcomes Executive Vice President of Engineering and Operations
Apr 07, 2015: Cepheid Welcomes Executive Vice President And Chief Financial Officer
Legal and Regulatory
Jan 07, 2016: USAID And Cepheid Plan Collaboration To Accelerate Global Diagnosis Of Multidrug-Resistant Tuberculosis
Product News
Mar 09, 2016: Cepheid Announces First FDA-Cleared Test for Detection of Carbapenem Resistance Genes in Isolates of Multidrug Resistant 'Superbugs'
Dec 07, 2015: Cepheid Obtains FDA 510(k) Approval For Xpert Flu+RSV Xpress Test
Jul 29, 2015: 'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms
Jul 28, 2015: Cepheid Launches New Portable Molecular Diagnostics System At AACC
May 13, 2015: WHO Lists Cepheid's Xpert Ebola as Eligible for Procurement to Ebola Affected Countries
Apr 16, 2015: Cepheid And FIND's Xpert HIV-1 Qual Test Receives European Approval
Apr 15, 2015: Cepheid Announces European Approval of Xpert HCV Viral Load
Mar 24, 2015: Cepheid's Xpert Ebola Diagnostic Test Gets FDA Emergency Use Authorisation
Mar 24, 2015: On World TB Day 2015 Cepheid and NHLS Commemorate Global Shipment of the 10 Millionth Xpert MTB/RIF Test Cartridge
Feb 13, 2015: Cepheid Receives FDA Clearance for Expanded Claims on Tuberculosis Test
Product Approvals
Mar 09, 2016: Cepheid Announces First FDA-Cleared Test for Detection of Carbapenem Resistance Genes in Isolates of Multidrug Resistant 'Superbugs'
Dec 07, 2015: Cepheid Obtains FDA 510(k) Approval For Xpert Flu+RSV Xpress Test
Apr 16, 2015: Cepheid And FIND's Xpert HIV-1 Qual Test Receives European Approval
Apr 15, 2015: Cepheid Announces European Approval of Xpert HCV Viral Load
Mar 24, 2015: Cepheid's Xpert Ebola Diagnostic Test Gets FDA Emergency Use Authorisation
Feb 13, 2015: Cepheid Receives FDA Clearance for Expanded Claims on Tuberculosis Test
Other Significant Developments
Apr 21, 2016: Cepheid Announces Partner Distribution Agreement With Medline
Dec 01, 2015: Cepheid Reaffirms 2015 Outlook At Piper Jaffray Healthcare Conference
Jun 10, 2015: New Approach on HIV Viral Load Testing
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer 72

LIST OF TABLES

Cepheid, Medical Equipment, Key Facts, 2015
Cepheid, Medical Equipment, Deals Summary, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals By Year, 2010 to YTD 2016
Cepheid, Medical Equipment Deals By Type, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals By Region, 2010 to YTD 2016
Cepheid, Deals By Market, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals Summary, 2010 to YTD 2016
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics
Quidel Enters Into Licensing Agreement With Northwestern University And Northwestern Global Health Foundation
Novacyt Enters into Partnership with Cepheid
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University
InGen BioSciences Enters Into Distribution Agreement With Quidel
InGen BioSciences Enters Into Distribution Agreement With Diagnostic Hybrids
Life Technologies Enters Into Co-Marketing Agreement With Quidel
Cepheid Enters Into Co-Development Agreement With FIND
Cepheid Enters Into Collaboration With Novartis
Cepheid Terminates Licensing Agreement With Roche
Quidel Completes Underwritten Public Offering Of US$60 Million
Quidel Prices Public Offering of 3.25% Senior Notes Due 2020
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million
Danaher to Acquire Cepheid
Quidel Acquires AnDiaTec, Molecular Diagnostics Company
Quidel Acquires BioHelix, Molecular Diagnostic Company, For US$10 Million
Quidel Completes Acquisition Of Diagnostic HYBRIDS
Cepheid, Key Competitors
Cepheid, Key Employees
Cepheid, Subsidiaries 40

LIST OF FIGURES

Cepheid, Medical Equipment, Deals by Type, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals By Year, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals By Region, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals By Market, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals By Year, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals by Type, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals By Region, 2010 to YTD 2016
Cepheid, Medical Equipment, Deals by Market, 2010 to YTD 2016
Skip to top


Ask Your Question

Cepheid (CPHD) - Medical Equipment - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: